TABLE 1

Analysis of T-cells during FTY720 treatment

PancreasPLNILNSpleen
Total cell number (×106)
    ControlND2.73 ± 1.40*9.97 ± 3.50*79.6 ± 25.9*
    FTY720 treatedND3.16 ± 0.803.65 ± 1.0331.7 ± 15.2
% CD4+ of CD45+ cells
    Control26.2 ± 9.6*48.5 ± 1.5*51.4 ± 7.5*28.3 ± 4.7*
    FTY720 treated9.3 ± 1.932.4 ± 1.827.8 ± 3.313.1 ± 2.6
Total CD4+ cell number (×106)
    ControlND1.32 ± 0.674.99 ± 1.47*21.6 ± 4.48*
    FTY720 treatedND1.02 ± 0.261.00 ± 0.254.07 ± 1.95
% Foxp3+ of CD4+ cells
    Control17.3 ± 6.821.6 ± 5.711.8 ± 2.6*17.9 ± 4.2
    FTY720 treated26.5 ± 9.824.3 ± 3.327.2 ± 2.320.0 ± 3.1
Total CD4+Foxp3+ cell number (×106)
    ControlND0.28 ± 0.150.60 ± 0.23*3.91 ± 1.33*
    FTY720 treatedND0.25 ± 0.070.27 ± 0.070.84 ± 0.45
% CD8+ of CD45+ cells
    Control7.2 ± 5.319.8 ± 2.6*20.5 ± 2.4*12.5 ± 2.0*
    FTY720 treated4.0 ± 4.131.9 ± 3.331.5 ± 3.44.0 ± 1.0
Total CD8+ cell number (×106)
    ControlND0.54 ± 0.29*2.02 ± 0.73*9.86 ± 3.31*
    FTY720 treatedND1.01 ± 0.281.13 ± 0.261.25 ± 0.59
  • NOD female mice were treated for 10 weeks with FTY720 beginning at 10–12 weeks of age. Mice were analyzed on the last day of treatment. Total cell number and percentages of CD4+ and CD8+ lymphocytes among CD45+ cells and CD4+Foxp3+ cells among CD4+ cells were determined by flow cytometry. Mean values of 3 independent treatment experiments are shown. Control n = 8. FTY720 treated n = 11. ND, not determined.

  • *P < 0.01 between control and FTY720 treated in the same tissue.